<?xml version="1.0" encoding="UTF-8"?>
<clinical_study rank="2468">
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on December 16, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT05129033</url>
  </required_header>
  <id_info>
    <org_study_id>2020ZSLC26</org_study_id>
    <nct_id>NCT05129033</nct_id>
  </id_info>
  <brief_title>A Prospective Study on Optimizing Treatment for ABPA</brief_title>
  <official_title>A Prospective, Two-center, Clinical Study to Optimize the Treatment for Allergic Bronchopulmonary Aspergillosis (ABPA)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Shanghai Zhongshan Hospital</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Shanghai Zhongshan Hospital</source>
  <oversight_info>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      This study is being done to evaluate the efficacy of treatment using oral glucocorticoid,&#xD;
      anti-fungal agent, anti-IgE mAb for patient with ABPA.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      This is a study randomly treating ABPA patients with either anti-fungal agent plus OCS or&#xD;
      anti-IgE mAb (omalizumab) plus OCS.&#xD;
&#xD;
      OCS is the basic treatment for ABPA by suppressing allergy and inflammation. Prednisone&#xD;
      tablets is given orally 0.5mg/kg/d for 4 weeks and gradually reduced to for a total usage of&#xD;
      6 months. Reduction may failed if disease exacerbate.&#xD;
&#xD;
      Anti-fungal agent (mainly itraconazole) could reduce the load of fungus but its application&#xD;
      is still controversial. The investigators use itraconazole 200mg bid for 8 months and 100mg&#xD;
      bid for another 8 months.&#xD;
&#xD;
      Omalizumab was given 600mg q4w for at least 6 months. The investigators use Anti-fungal agent&#xD;
      and Omalizumab as a supplement to OCS to evaluate the better treatment plan for ABPA&#xD;
      patients.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">November 15, 2021</start_date>
  <completion_date type="Anticipated">December 30, 2023</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2023</primary_completion_date>
  <phase>N/A</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Parallel Assignment</intervention_model>
    <primary_purpose>Treatment</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>incidence of exacerbation: the exacerbation times indicated by symptoms and clinical index</measure>
    <time_frame>Up to 6 months after last treatment dose</time_frame>
    <description>the exacerbation times indicated by symptoms and clinical index, including commom respiratory symptoms such as wheezing, cough, expectation, dyspnea and so on. As well as new shadows in chest CT. Those situation may cause the extreme clinic visit and hospitalization, which could be measured by times or days.</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>ST.George's respiratory questionnaire</measure>
    <time_frame>Up to 6 months after last treatment dose</time_frame>
    <description>The SGRQ is a classic respiratory questionnaire including the symptoms, activity, and impact to life. The higher score means better disease control.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>asthma control test questionnaire</measure>
    <time_frame>Up to 6 months after last treatment dose</time_frame>
    <description>The ACT is a classic asthma questionnaire recommended by GINA (Global Initiative for Asthma). ACT mainly measures the symptoms. The higher score means better disease control.</description>
  </secondary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Anticipated">100</enrollment>
  <condition>Allergic Bronchopulmonary Aspergillosis</condition>
  <arm_group>
    <arm_group_label>anti-fungal agent plus OCS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prednisone tablets is given orally 0.5mg/kg/d for 4 weeks and gradually reduced to stop for a total usage of 6 months Itraconazole is given orally 200mg bid for 8 months and 100mg bid for another 8 months</description>
  </arm_group>
  <arm_group>
    <arm_group_label>anti-IgE mAb plus OCS</arm_group_label>
    <arm_group_type>Active Comparator</arm_group_type>
    <description>Prednisone tablets is given orally 0.5mg/kg/d for 4 weeks and gradually reduced to stop for a total usage of 6 months Omalizumab is given by subcutaneous injection of 600mg q4w for at least 6 months</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Prednisone tablet</intervention_name>
    <description>Basic medication for allergic airway inflammation such as asthma and ABPA, to relieve inflammation. Reduction may failed if disease exacerbate.</description>
    <arm_group_label>anti-IgE mAb plus OCS</arm_group_label>
    <arm_group_label>anti-fungal agent plus OCS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>itraconazole</intervention_name>
    <description>Anti-fungal medication to reduce fugal load.</description>
    <arm_group_label>anti-fungal agent plus OCS</arm_group_label>
  </intervention>
  <intervention>
    <intervention_type>Biological</intervention_type>
    <intervention_name>Omalizumab</intervention_name>
    <description>Anti-IgE monoclonal antibody, used for high IgE allergic disease.</description>
    <arm_group_label>anti-IgE mAb plus OCS</arm_group_label>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18~75 years old, male or female&#xD;
&#xD;
          -  associated past medical history, including asthma, bronchiectasis, COPD ect.&#xD;
&#xD;
          -  elevated serum total IgE (&gt;100IU/mL)&#xD;
&#xD;
          -  elevated aspergillus specific IgE&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  According to the investigator, the patient has other factors that may affect the&#xD;
             results of the study or lead to the termination of the study, such as alcohol abuse,&#xD;
             drug abuse, other serious diseases (including mental illness).&#xD;
&#xD;
          -  Pregnancy or breastfeeding&#xD;
&#xD;
          -  Abnormality of liver or kidney function&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>75 Years</maximum_age>
    <healthy_volunteers>Accepts Healthy Volunteers</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Meiling Jin, MD</last_name>
    <role>Study Chair</role>
    <affiliation>Department of Respiratory, Zhongshan Hospital, Fudan University Shanghai, China</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Meiling Jin, MD</last_name>
    <phone>+86 13701640522</phone>
    <email>mljin118@163.com</email>
  </overall_contact>
  <reference>
    <citation>Agarwal R. Allergic bronchopulmonary aspergillosis. Chest. 2009 Mar;135(3):805-826. doi: 10.1378/chest.08-2586. Review.</citation>
    <PMID>19265090</PMID>
  </reference>
  <reference>
    <citation>Agarwal R, Aggarwal AN, Gupta D, Jindal SK. Aspergillus hypersensitivity and allergic bronchopulmonary aspergillosis in patients with bronchial asthma: systematic review and meta-analysis. Int J Tuberc Lung Dis. 2009 Aug;13(8):936-44. Review.</citation>
    <PMID>19723372</PMID>
  </reference>
  <reference>
    <citation>Agarwal R, Nath A, Aggarwal AN, Gupta D, Chakrabarti A. Aspergillus hypersensitivity and allergic bronchopulmonary aspergillosis in patients with acute severe asthma in a respiratory intensive care unit in North India. Mycoses. 2010 Mar 1;53(2):138-43. doi: 10.1111/j.1439-0507.2008.01680.x. Epub 2009 Jan 24.</citation>
    <PMID>19207831</PMID>
  </reference>
  <reference>
    <citation>Agarwal R, Chakrabarti A, Shah A, Gupta D, Meis JF, Guleria R, Moss R, Denning DW; ABPA complicating asthma ISHAM working group. Allergic bronchopulmonary aspergillosis: review of literature and proposal of new diagnostic and classification criteria. Clin Exp Allergy. 2013 Aug;43(8):850-73. doi: 10.1111/cea.12141. Review.</citation>
    <PMID>23889240</PMID>
  </reference>
  <reference>
    <citation>Mou Y, Ye L, Ye M, Yang D, Jin M. A retrospective study of patients with a delayed diagnosis of allergic bronchopulmonary aspergillosis/allergic bronchopulmonary mycosis. Allergy Asthma Proc. 2014 Mar-Apr;35(2):e21-6. doi: 10.2500/aap.2014.35.3731.</citation>
    <PMID>24717781</PMID>
  </reference>
  <reference>
    <citation>Agarwal R, Gupta D, Aggarwal AN, Saxena AK, Chakrabarti A, Jindal SK. Clinical significance of hyperattenuating mucoid impaction in allergic bronchopulmonary aspergillosis: an analysis of 155 patients. Chest. 2007 Oct;132(4):1183-90. Epub 2007 Jul 23.</citation>
    <PMID>17646221</PMID>
  </reference>
  <verification_date>November 2021</verification_date>
  <study_first_submitted>July 3, 2021</study_first_submitted>
  <study_first_submitted_qc>November 19, 2021</study_first_submitted_qc>
  <study_first_posted type="Actual">November 22, 2021</study_first_posted>
  <last_update_submitted>November 19, 2021</last_update_submitted>
  <last_update_submitted_qc>November 19, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">November 22, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Allergic Bronchopulmonary Aspergillosis</keyword>
  <keyword>anti-fungal agent</keyword>
  <keyword>Omalizumab</keyword>
  <keyword>oral corticosteroids</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Aspergillosis</mesh_term>
    <mesh_term>Pulmonary Aspergillosis</mesh_term>
    <mesh_term>Aspergillosis, Allergic Bronchopulmonary</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Omalizumab</mesh_term>
    <mesh_term>Itraconazole</mesh_term>
    <mesh_term>Prednisone</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>No</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

